Even before the Supreme Court overturned Roe v. Wade in June 2022, the United States lagged in providing adequate reproductive health services for female-specific conditions including contraception, gynecology, fertility, maternal health, women’s oncology, and menopause. Once considered a niche market—underfunded, underserved, and overlooked—women's reproductive health is now acknowledged as an essential area of research and investment. Reproductive care enterprises are seeing more mission-driven impact investments from private investors and philanthropic organizations, but the market is still critically underfunded. This session will explore the challenges and opportunities in creating an ecosystem comprised of research, innovation, investment, and partnerships to enhance funding and advancement for this critical area of health care. 

Moderator

Alice Miranda Ollstein

Health Care Reporter, Politico

Speakers

Alison Cernich

Deputy Director, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health

Diana Contreras

Chief Health Strategy Officer, Planned Parenthood Federation of America

Robin Marty

Executive Director, West Alabama Women's Center

Neel Shah

Chief Medical Officer, Maven Clinic

Alice Zheng

Principal, RH Capital